• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

MAUDE Adverse Event Report: PENUMBRA, INC. PENUMBRA SYSTEM RED 62 REPERFUSION CATHETER; NRY

  • Print
  • Share
  • E-mail
-
Super Search Devices@FDA
510(k) | DeNovo | Registration & Listing | Adverse Events | Recalls | PMA | HDE | Classification | Standards
CFR Title 21 | Radiation-Emitting Products | X-Ray Assembler | Medsun Reports | CLIA | TPLC
 

PENUMBRA, INC. PENUMBRA SYSTEM RED 62 REPERFUSION CATHETER; NRY Back to Search Results
Catalog Number RED62S
Medical Device Problem Code Fracture (1260)
Health Effect - Clinical Code No Clinical Signs, Symptoms or Conditions (4582)
Date of Event 11/12/2023
Type of Reportable Event Malfunction
Event or Problem Description
The patient was undergoing a thrombectomy procedure in the right m1 segment of the middle cerebral artery (mca) using a penumbra system red 62 reperfusion catheter (red62), a non-penumbra sheath, a non-penumbra microcatheter, a non-penumbra stent retriever and a guidewire.It was noted that the patient''s anatomy was tortuous.During the procedure, while retracting the red62 after first pass aspiration, the red62 fractured mid-shaft.It was reported that the sheath was noticed to be kinked under fluoroscopy.The physician then removed the red62 with the entire system.The procedure ended at this point.The physician could not regain access once the entire system was removed.The patient was placed on comfort care and expired later that day.The cause of death was retroperitoneal hematoma.
 
Additional Manufacturer Narrative
Evaluation of the returned red62 confirmed that the catheter was fractured.If the red62 is retracted against resistance, damage such as a fracture may occur.The tortuous patient anatomy and kink in the non-penumbra device likely contributed to resistance during the procedure.Further evaluation revealed ovalization and stretching on the catheter shaft.This damage was incidental to the reported complaint and the root cause could not be determined.Penumbra catheters are inspected during in-process inspection and during quality inspection after manufacturing.The manufacturing records for this lot were reviewed and did not reveal any outstanding discrepancies, design, or quality concerns.H3 other text : placeholder.
 
Search Alerts/Recalls

  New Search  |  Submit an Adverse Event Report

Brand Name
PENUMBRA SYSTEM RED 62 REPERFUSION CATHETER
Common Device Name
NRY
Manufacturer (Section D)
PENUMBRA, INC.
one penumbra place
alameda CA 94502
Manufacturer Contact
veronica farris
one penumbra place
alameda, CA 94502
5107483200
MDR Report Key18297508
Report Number3005168196-2023-00544
Device Sequence Number12610354
Product Code NRY
UDI-Device Identifier00815948023475
UDI-Public815948023475
Combination Product (Y/N)N
Initial Reporter StatePA
Initial Reporter CountryUS
PMA/510(K) Number
K203440
Number of Events Summarized1
Summary Report (Y/N)N
Reporter Type Manufacturer
Report Source Health Professional,Company Representative
Initial Reporter Occupation Physician
Type of Report Initial
Report Date (Section B) 12/08/2023
Report Date (Section F) 01/01/2005
1 Device was Involved in the Event
1 Patient was Involved in the Event
Is this an Adverse Event Report? No
Is this a Product Problem Report? Yes
Operator of Device Health Professional
Device Expiration Date04/09/2026
Device Catalogue NumberRED62S
Device Lot NumberF00006305
Was Device Available for Evaluation? Device Returned to Manufacturer
Date Returned to Manufacturer11/20/2023
Is the Reporter a Health Professional? Yes
Was the Report Sent to FDA? Yes
Date Report to Manufacturer01/10/2005
Type of Report(Section G)Thirty-Day
Initial Date Received by Manufacturer 11/15/2023
Initial Report FDA Received Date12/08/2023
Was Device Evaluated by Manufacturer? (Y/N) Yes
Date Device Manufactured04/10/2023
Is the Device Labeled for Single Use? (Y/N) Yes
Is This a Single-Use Device that was
Reprocessed and Reused on a Patient? (Y/N)
No
Usage of Device Initial
Patient Sequence Number1
Patient SexFemale
Date Report Sent to FDA01/01/2005
-
-